Stocks
Neurogene Inc.NGNE
NASDAQHealthcareBiotechnology$23.52
Price as of · delayed, not real-time
A clinical-stage gene therapy company developing treatments for rare neurological disorders. Its lead program targets a form of Parkinson's disease, and it is advancing a pipeline of adeno-associated virus-based therapies. Investors track the company for its potential to address unmet needs in neurology and for its progress through clinical trials.
52W Range: $15.93-$43.66
Congressional Interest in Neurogene Inc. (NGNE)
No congressional trades have been disclosed for Neurogene Inc. (NGNE) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading NGNE?
No congressional trades found for this stock.